이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Safe Bay 3713372가 얼마나 Safe Bay 3713372가 MTAP 삭제 된 고형 종양을 가진 참가자에게 어떻게 작동하는지 배우기위한 최초의 연구

2026년 11월 10일 업데이트: Bayer

MTAP- 삭제 된 고형 종양을 가진 참가자에서 안전, 내약성 및 약동학, 약물 역학 및 예비 임상 활동, BAY 3713372의 BAY 3713372의 최초의 인간 연구.

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.

The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.

For this, the researchers will study and analyze:

  • the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.
  • the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.
  • the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.
  • the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.

Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.

The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.

Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.

Participants will visit the study site:

  • at least twice before the treatment starts
  • multiple times when they start taking the treatment
  • once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason

During the study, the doctors and their study team will:

  • check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram
  • check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan
  • take tumor samples

The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.

연구 개요

상태

모병

개입 / 치료

연구 유형

중재적

등록 (추정된)

450

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • North Holland
      • Amsterdam, North Holland, 네덜란드, 1066 CX
        • 모병
        • Nederlands Kanker Instituut
    • Provincie Groningen
      • Groningen, Provincie Groningen, 네덜란드, 9713 GZ
        • 아직 모집하지 않음
        • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
    • South Holland
      • Rotterdam, South Holland, 네덜란드, 3015 CE
        • 모병
        • Erasmus Medisch Centrum
    • Capital Region / Region Hovedstaden
      • Copenhagen, Capital Region / Region Hovedstaden, 덴마크, 2100
        • 모병
        • Rigshospitalet Copenhagen University Hospital | Oncology Department
    • Region of Southern Denmark / Region Syddanmark
      • Odense, Region of Southern Denmark / Region Syddanmark, 덴마크, 5000
        • 모병
        • Odense University Hospital | Svendborg Sygehus - Oncology Department
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 아직 모집하지 않음
        • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
    • California
      • Duarte, California, 미국, 91010
        • 아직 모집하지 않음
        • City of Hope - Duarte Cancer Center
      • Los Angeles, California, 미국, 90095
        • 아직 모집하지 않음
        • UCLA Health Bowyer Oncology Center
      • San Francisco, California, 미국, 94143
        • 모병
        • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
      • Stanford, California, 미국, 94305
        • 아직 모집하지 않음
        • Stanford University Medical Center - Neurology
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 아직 모집하지 않음
        • UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
      • Denver, Colorado, 미국, 80218
        • 모병
        • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
    • Florida
      • Orlando, Florida, 미국, 32827
        • 모병
        • Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 아직 모집하지 않음
        • Dana-Farber Cancer Institute - Oncology Department
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital - Neurology
    • Michigan
      • Grand Rapids, Michigan, 미국, 49546
        • 모병
        • START | Midwest
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center New York - Main Campus
      • New York, New York, 미국, 10029
        • 모병
        • Icahn School of Medicine at Mount Sinai - Oncology
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • SCRI Oncology Partners
    • Texas
      • Irving, Texas, 미국, 75039
        • 모병
        • NEXT Dallas - Oncology Department
      • San Antonio, Texas, 미국, 78229
        • 모병
        • START | San Antonio
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • 아직 모집하지 않음
        • Froedtert Hospital - Clinical Cancer Center
    • Antwerp
      • Antwerp, Antwerp, 벨기에, 2650
        • 모병
        • Antwerp University Hospital | Oncology Department
    • East Flanders
      • Ghent, East Flanders, 벨기에, 9000
        • 모병
        • Ghent University Hospital | Drug Research Unit Department
    • Flemish Brabant
      • Leuven, Flemish Brabant, 벨기에, 3000
        • 모병
        • UZ Leuven Gasthuisberg - Pneumology Department
    • Liège
      • Liège, Liège, 벨기에, 4000
        • 모병
        • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
    • Stockholm County
      • Stockholm, Stockholm County, 스웨덴, 171 76
        • 모병
        • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, 스웨덴, 413 46
        • 아직 모집하지 않음
        • Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
    • Barcelona
      • Barcelona, Barcelona, 스페인, 08023
        • 모병
        • Hospital Hm Nou Delfos | Oncologia
      • Barcelona, Barcelona, 스페인, 08035
        • 모병
        • Hospital Universitari Vall D Hebron | Oncologia
    • Chartered Community of Navarre
      • Pamplona, Chartered Community of Navarre, 스페인, 31008
        • 모병
        • Clinica Universidad De Navarra | Pamplona | Oncologia
    • La Rioja
      • Logroño, La Rioja, 스페인, 26006
        • 모병
        • Hospital San Pedro | Oncologia
    • Madrid
      • Madrid, Madrid, 스페인, 28040
        • 모병
        • Hospital Universitario Fundacion Jimenez Diaz | Oncologia
      • Pozuelo de Alarcón, Madrid, 스페인, 28223
        • 모병
        • NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
    • Málaga
      • Málaga, Málaga, 스페인, 29010
        • 모병
        • Hospital Universitario Virgen De La Victoria | Oncologia
    • Valencia
      • Valencia, Valencia, 스페인, 46010
        • 아직 모집하지 않음
        • Hospital Clinico Universitario De Valencia | Oncologia
    • Singapore
      • Singapore, Singapore, 싱가포르, 119074
        • 모병
        • National University Hospital Medical Centre
      • Singapore, Singapore, 싱가포르, 168583
        • 모병
        • National Cancer Center Singapore - Oncology Department
      • Singapore, Singapore, 싱가포르, 217562
        • 모병
        • Icon Cancer Centre
    • Greater Manchester
      • Manchester, Greater Manchester, 영국, M20 4BX
        • 모병
        • The Christie Hospital | Experimental Cancer Medicine Team
    • Surrey
      • Sutton, Surrey, 영국, SM2 5PT
        • 아직 모집하지 않음
        • The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
    • Friuli Venezia Giulia
      • Aviano, Friuli Venezia Giulia, 이탈리아, 33081
        • 모병
        • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
    • Lazio
      • Rome, Lazio, 이탈리아, 00128
        • 모병
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
      • Rome, Lazio, 이탈리아, 00144
        • 아직 모집하지 않음
        • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
    • Lombardy
      • Milan, Lombardy, 이탈리아, 20133
        • 모병
        • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
      • Rozzano, Lombardy, 이탈리아, 20089
        • 모병
        • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 466-8560
        • 아직 모집하지 않음
        • Nagoya University Hospital
    • Osaka
      • Sakai, Osaka, 일본, 590-0197
        • 모병
        • Kindai University Hospital
    • Shizuoka
      • Sunto, Shizuoka, 일본, 411-8777
        • 모병
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo-ku, Tokyo, 일본, 104-0045
        • 모병
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, 일본, 135-8550
        • 모병
        • The Cancer Institute Hospital of JFCR
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100142
        • 모병
        • Beijing Cancer Hospital - Oncology Department
      • Beijing, Beijing Municipality, 중국, 101149
        • 아직 모집하지 않음
        • Beijing chest hospital, Capital Medical University
    • Hubei
      • Wuhan, Hubei, 중국, 430075
        • 모병
        • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210029
        • 아직 모집하지 않음
        • Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310016
        • 아직 모집하지 않음
        • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
    • Olomouc Region
      • Olomouc, Olomouc Region, 체코, 779 00
        • 모병
        • Fakultní nemocnice Olomouc - Onkologická klinika
    • South Moravian
      • Brno, South Moravian, 체코, 602 00
        • 모병
        • Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
    • New South Wales
      • Camperdown, New South Wales, 호주, 2050
        • 모병
        • Chris O'Brien Lifehouse
      • Concord, New South Wales, 호주, 2139
        • 모병
        • Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
      • Epping, New South Wales, 호주, 3076
        • 아직 모집하지 않음
        • Northern Hospital
      • Waratah, New South Wales, 호주, 2298
        • 모병
        • Calvary Mater Hospital Newcastle - Oncology

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent.
  • At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
  • Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

  • Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.

  • A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.

  • Cardiac history comprising:

    • History of congestive heart failure Class >II according to the New York Heart Association Functional Classification.
    • Myocardial infarction less than 6 months before the start of study intervention.
    • Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.
  • Unstable angina within 4 weeks before start of study intervention.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Dose Escalation (Intervention Cohort 1)

For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned.

Daily oral administration

실험적: Backfill cohorts in Intervention Cohort 1 (Dose Escalation)

Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development.

Daily oral administration

실험적: Dose Expansion (Intervention Cohort 1)

Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors.

Daily oral administration

실험적: Dose Expansion (Intervention Cohort 2)

Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC).

Daily oral administration

실험적: Dose Expansion (Intervention Cohort 3)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

Daily oral administration

실험적: Dose Expansion (Intervention Cohort 4)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

Daily oral administration

실험적: Dose Expansion (Intervention Cohort 5)

Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).

Daily oral administration

실험적: Dose Expansion (Intervention Cohort 6)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC.

Daily oral administration

실험적: Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)

A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM).

Daily oral administration

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
용량 에스컬레이션 (마스터 및 중재 코호트 1) : 베이의 각각의 투여 간격의 최대 농도 (CMAX) 3713372
기간: 연구 중재의 첫 번째 복용량부터 사이클 2 일까지 (각주기는 21 일)
연구 중재의 첫 번째 복용량부터 사이클 2 일까지 (각주기는 21 일)
복용량 에스컬레이션 (마스터 및 중재 코호트 1) : 베이의 각각의 투여 간격의 곡선 (AUC)의 영역 3713372
기간: 연구 중재의 첫 번째 복용량부터 사이클 2 일까지 (각주기는 21 일)
연구 중재의 첫 번째 복용량부터 사이클 2 일까지 (각주기는 21 일)
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)
기간: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs
기간: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)
기간: Approximately 1.5 years

Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Approximately 1.5 years
Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs
기간: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Intervention Cohort 7: Number of participants with DLTs
기간: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372
기간: From first dose through day of surgery (approximately 7 ± 2 days)

Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios

From first dose through day of surgery (approximately 7 ± 2 days)
Intervention Cohort 7: Tumor tissue SDMA levels
기간: From first dose through day of surgery (approximately 7 ± 2 days)

Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition

From first dose through day of surgery (approximately 7 ± 2 days)

2차 결과 측정

결과 측정
측정값 설명
기간
복용량 에스컬레이션 (마스터 및 중재 코호트 1) : 응답 시간 (TTR)
기간: 약 1.5 년
약 1.5 년
용량 확장 (마스터, 중재 코호트 1-6) : 응답 시간 (TTR)
기간: 약 1.5 년
약 1.5 년
용량 팽창 (마스터, 중재 코호트 1-4 및 6) : Bay 3713372의 각각의 투여 간격의 최대 농도 (CMAX)
기간: 연구 중재의 첫 번째 복용량에서 사이클 2 일까지 (각주기는 21 일입니다.
연구 중재의 첫 번째 복용량에서 사이클 2 일까지 (각주기는 21 일입니다.
용량 확장 (마스터, 중재 코호트 1-4 및 6) : 각각의 투여 간격의 곡선 (AUC) 아래 면적 3713372
기간: 연구 중재의 첫 번째 복용량에서 사이클 2 일까지 (각주기는 21 일입니다.
연구 중재의 첫 번째 복용량에서 사이클 2 일까지 (각주기는 21 일입니다.
Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)
기간: Approximately 3 years
Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases
기간: Approximately 1.5 years
Approximately 1.5 years
Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)
기간: Approximately 1.5 years

Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Approximately 1.5 years
Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)
기간: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)
기간: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
기간: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)
기간: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)
기간: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)
기간: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases
기간: Approximately 1.5 years

CNS-ORR: CNS objective response rate

Approximately 1.5 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases
기간: Approximately 3 years

CNS-DOR: Duration of CNS response

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases
기간: Approximately 3 years

CNS-PFS: Survival without CNS progression

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases
기간: Approximately 1.5 years

CNS-TTR: Time to CNS response

Approximately 1.5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 21일

기본 완료 (추정된)

2029년 6월 18일

연구 완료 (추정된)

2029년 6월 18일

연구 등록 날짜

최초 제출

2025년 3월 31일

QC 기준을 충족하는 최초 제출

2025년 3월 31일

처음 게시됨 (실제)

2025년 4월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다